Zinc supplementation in patients with Head and Neck Cancer in Radiotherapy
Not Applicable
- Conditions
- DysgeusiaE02.815
- Registration Number
- RBR-104bdhff
- Lead Sponsor
- iga Norte Riograndense Contra o Câncer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with head and neck cancer; age between 19 and 65 years; under radiotherapy treatment, of both genders.
Exclusion Criteria
Gastrointestinal tract disorders; exclusive alternative food route, such as total parenteral nutrition (TPN) and enteral nutritional therapy (ENT); Exocrine pancreatic insufficiency; Tongue or palate demolition surgery; Sjögren's syndrome, considering that the pathophysiology of this disease can affect the salivary glands and impair taste; Diagnosis for Covid-19 with presence of dysgeusia
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the degree of dysgeusia obtained between time T1 and T30 of zinc supplementation and to compare the experimental and control groups after 30 days of radiotherapy using the supplement.;Measure dysgeusia by the perception of flavors such as sweet, salty, sour, bitter and tasteless” and the intensity in the following variants: very strong, strong, moderate, weak, very weak”, through sensory analysis.
- Secondary Outcome Measures
Name Time Method To analyze adherence to supplementation assessed by the Morisky-Green scale and vial count.;Follow the weight monitored by the nutritional assessment.;Assess food acceptance according to the percentage obtained by the validated tool BRASPE